Atlas Trials

Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis

Clinical trial NCT04818671 · COMPLETED

Trial details

NCT number
NCT04818671
Sponsor
argenx
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Generalized Myasthenia Gravis
Start date
2021-04-26
Primary completion
2024-12-31
Enrollment
184

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.